



**Alliance for Clinical Trials in Oncology**  
**Friday, May 15, 2015**  
**Loews Chicago O'Hare Hotel**  
**Louvre 1**  
**1 pm – 4:30 pm**

## **Neuro-Oncology Committee Meeting Agenda**

Chair: Evanthia Galanis, MD

### **Welcome – Overview**

E. Galanis

### **Active Protocols and Concepts in Development**

#### **Newly Diagnosed GBM**

N0874 Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) [SAHA]Temozolomide, and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma (Completed) E. Galanis/P. Wen

N0877 Phase I Randomized Phase II Trial of Either Dasatanib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM) E. Galanis  
(Accrual goal met on 12/6/13-ASCO presentation)

Phase I/II Study of AZD1775 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma B. Alexander

A071102: Randomized Trial of ABT-888 or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed GBM with MGMT Promoter Hypermethylation J. Sarkaria

Individualized Screening trial of Innovative Glioblastoma Therapy (INSIGHt) B. Alexander

A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 in Newly Diagnosed Glioblastoma Following Resection and Chemoradiation. P.Wen

## **Recurrent GBM**

- N0872 Phase I Randomized Phase II Double Blinded Study of Either Dasatanib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma (Accrual goal met on 3/27/14, ASCO presentation) E. Galanis
- A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPCC-96) NSC #725085, BB IND# Pending) Vaccine Given with Bevacizumab versus Bevacizumab alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM) E. Galanis/  
E. Horvath
- N1174: Phase I/Randomized Comparative Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme E. Galanis/P.Wen

## **Anaplastic Gliomas – Newly Diagnosed**

- N0577 Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma K. Jaeckle
- EORTC 26053-22054 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma: The CATNON Intergroup Trial K. Jaeckle

## **Low Grade Gliomas**

- E3F05 Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas (Temp. Closed) D. Schiff

## **Meningiomas**

- A071401: Phase II Trial of SMO/AKT Inhibitors in Progressive Meningiomas with SMO/AKT Mutations P. Brastianos

## **Craniopharyngiomas**

- A071501: Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas P. Brastianos

## **Brain Metastases**

N0574 A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) (Accrual goal met on 11/8/13, ASCO presentation) P. Brown

N017C A Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy In Addition to Radiosurgery in the Management of Patients with One to Three Cerebral Metastases P. Brown/  
E. Sulman

Molecularly-driven Trial in Brain Metastases P. Brastianos

## **Symptom Control**

A221101: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil<sup>®</sup>) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme A. Porter

A221208: Bevacizumab vs. Steroids (BeSt) for Radionecrosis After Radiosurgery: A Randomized Phase II Trial C. Chung/  
E. Sulman

## **Neuro-Oncology Imaging Subcommittee**

Introduction to the Neuro-Oncology Imaging Subcommittee T. Kaufmann